<p>Aadi Bioscience, Inc.（納斯達克：AADI - 獲取免費報告）首席執行官 David James Lennon 於 3 月 3 日星期一出售了 5,690 股公司股票。該股票以平均價格 2.35 美元出售，總價值為 13,371.50 美元。出售後，首席執行官現在擁有 33,429 股公司股票，估值約為 78,558.15 美元。此次交易代表其持股減少了 14.55%。該交易已在向 SEC 提交的文件中披露，您可以通過此鏈接訪問。</p>
<p>獲取 <strong>Aadi Bioscience</strong> 警報：</p>
<h2>Aadi Bioscience 股票表現</h2>
<p>週一交易時段，AADI 股價下跌 0.26 美元，報 2.30 美元。公司交易了 217,778 股，較其平均交易量 174,224 股有所增加。該公司的市值為 5680 萬美元，市盈率為-1.01，貝塔值為 0.64。該公司的 50 日移動平均線為 2.95 美元，200 日移動平均線為 2.37 美元。Aadi Bioscience, Inc.的 52 周最低價為 1.21 美元，52 周最高價為 3.81 美元。</p>
<h2>對 Aadi Bioscience 的對沖基金看法</h2>
<p>幾家大型投資者最近對該公司的持股進行了調整。XTX Topco Ltd 在第三季度新購入了 Aadi Bioscience 的股份，價值約 32,000 美元。Two Sigma Advisers LP 在第四季度將其在 Aadi Bioscience 的持股增加了 95.2%。Two Sigma Advisers LP 現在擁有 61,686 股公司股票，價值 195,000 美元，此前在上個季度又購買了 30,086 股。Two Sigma Investments LP 在第四季度將其在 Aadi Bioscience 的持股增加了 305.2%。Two Sigma Investments LP 現在擁有 68,555 股公司股票，價值 216,000 美元，此前在上個季度又購買了 51,638 股。Northern Trust Corp 在第四季度將其在 Aadi Bioscience 的持股增加了 33.1%。Northern Trust Corp 現在擁有 91,151 股公司股票，價值 288,000 美元，此前在上個季度又購買了 22,677 股。最後，Bridgeway Capital Management LLC 在第四季度將其在 Aadi Bioscience 的持股增加了 23.7%。Bridgeway Capital Management LLC 現在擁有 115,400 股公司股票，價值 364,000 美元，此前在上個季度又購買了 22,100 股。機構投資者和對沖基金持有公司 52.08% 的股份。</p>
<h2>Aadi Bioscience 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Aadi Bioscience, Inc.是一家生物製藥公司，專注於開發和商業化針對具有 mTOR 通路基因改變的基因定義癌症的精準療法。其主要藥物候選產品為 FYARRO，一種用於治療晚期不可切除或轉移性惡性 PEComa 的注射用西羅莫司蛋白結合顆粒。</p>
<h2>特色文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Aadi Bioscience</li>
<li>3 只小型股具有巨大的回報潛力</li>
<li>看跌投資者可以在抗衰退 ETF 中尋求避難所</li>
<li>什麼是股票市場指數，如何使用它們？</li>
<li>3 只超賣的七隻奇蹟股票處於關鍵水平：現在買入嗎？</li>
<li>3 只天然氣股票提供優厚的股息收益</li>
<li>3M 預計在年中達到 175 美元，且更高的高點可能性較大</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUFESQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUFESQ"/></p>
<p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Aadi Bioscience 嗎？</h2>
<p>在考慮 Aadi Bioscience 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 Aadi Bioscience 並不在名單上。</p>
<p>雖然 Aadi Bioscience 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

AADI

WHWK

<p>Aadi Bioscience, Inc. 首席執行官 David James Lennon 出售了 5,690 股股票，平均價格為 2.35 美元，總計 13,371.50 美元。出售後，他持有 33,429 股，價值約 78,558.15 美元，反映出其持股比例下降了 14.55%。該交易已向美國證券交易委員會（SEC）備案。Aadi 的股票交易價格下跌至 2.30 美元，市值為 5680 萬美元。機構投資者持有該公司 52.08% 的股份，該公司專注於針對基因定義癌症的精準治療</p>

<p>Aadi Bioscience, Inc. (NASDAQ:AADI - Get Free Report) CEO David James Lennon sold 5,690 shares of the company's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $2.35, for a total value of $13,371.50. Following the sale, the chief executive officer now owns 33,429 shares of the company's stock, valued at approximately $78,558.15. This trade represents a 14.55 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.</p>
<div class="lb-trans"><p>Aadi Bioscience, Inc.（納斯達克：AADI - 獲取免費報告）首席執行官 David James Lennon 於 3 月 3 日星期一出售了 5,690 股公司股票。該股票以平均價格 2.35 美元出售，總價值為 13,371.50 美元。出售後，首席執行官現在擁有 33,429 股公司股票，估值約為 78,558.15 美元。此次交易代表其持股減少了 14.55%。該交易已在向 SEC 提交的文件中披露，您可以通過此鏈接訪問。</p>
</div><p>Get <strong>Aadi Bioscience</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Aadi Bioscience</strong> 警報：</p>
</div><h2>Aadi Bioscience Stock Performance</h2>
<div class="lb-trans"><h2>Aadi Bioscience 股票表現</h2>
</div><p>Shares of AADI traded down $0.26 during trading hours on Monday, hitting $2.30. 217,778 shares of the company were exchanged, compared to its average volume of 174,224. The company has a market cap of $56.80 million, a PE ratio of -1.01 and a beta of 0.64. The firm's 50 day moving average is $2.95 and its 200-day moving average is $2.37. Aadi Bioscience, Inc. has a 52 week low of $1.21 and a 52 week high of $3.81.</p>
<div class="lb-trans"><p>週一交易時段，AADI 股價下跌 0.26 美元，報 2.30 美元。公司交易了 217,778 股，較其平均交易量 174,224 股有所增加。該公司的市值為 5680 萬美元，市盈率為-1.01，貝塔值為 0.64。該公司的 50 日移動平均線為 2.95 美元，200 日移動平均線為 2.37 美元。Aadi Bioscience, Inc.的 52 周最低價為 1.21 美元，52 周最高價為 3.81 美元。</p>
</div><h2>Hedge Funds Weigh In On Aadi Bioscience</h2>
<div class="lb-trans"><h2>對 Aadi Bioscience 的對沖基金看法</h2>
</div><p>Several large investors have recently made changes to their positions in the business. XTX Topco Ltd acquired a new position in shares of Aadi Bioscience during the 3rd quarter worth about $32,000. Two Sigma Advisers LP lifted its position in shares of Aadi Bioscience by 95.2% during the 4th quarter. Two Sigma Advisers LP now owns 61,686 shares of the company's stock worth $195,000 after purchasing an additional 30,086 shares during the last quarter. Two Sigma Investments LP lifted its position in shares of Aadi Bioscience by 305.2% during the 4th quarter. Two Sigma Investments LP now owns 68,555 shares of the company's stock worth $216,000 after purchasing an additional 51,638 shares during the last quarter. Northern Trust Corp lifted its position in shares of Aadi Bioscience by 33.1% during the 4th quarter. Northern Trust Corp now owns 91,151 shares of the company's stock worth $288,000 after purchasing an additional 22,677 shares during the last quarter. Finally, Bridgeway Capital Management LLC lifted its position in shares of Aadi Bioscience by 23.7% during the 4th quarter. Bridgeway Capital Management LLC now owns 115,400 shares of the company's stock worth $364,000 after purchasing an additional 22,100 shares during the last quarter. Institutional investors and hedge funds own 52.08% of the company's stock.</p>
<div class="lb-trans"><p>幾家大型投資者最近對該公司的持股進行了調整。XTX Topco Ltd 在第三季度新購入了 Aadi Bioscience 的股份，價值約 32,000 美元。Two Sigma Advisers LP 在第四季度將其在 Aadi Bioscience 的持股增加了 95.2%。Two Sigma Advisers LP 現在擁有 61,686 股公司股票，價值 195,000 美元，此前在上個季度又購買了 30,086 股。Two Sigma Investments LP 在第四季度將其在 Aadi Bioscience 的持股增加了 305.2%。Two Sigma Investments LP 現在擁有 68,555 股公司股票，價值 216,000 美元，此前在上個季度又購買了 51,638 股。Northern Trust Corp 在第四季度將其在 Aadi Bioscience 的持股增加了 33.1%。Northern Trust Corp 現在擁有 91,151 股公司股票，價值 288,000 美元，此前在上個季度又購買了 22,677 股。最後，Bridgeway Capital Management LLC 在第四季度將其在 Aadi Bioscience 的持股增加了 23.7%。Bridgeway Capital Management LLC 現在擁有 115,400 股公司股票，價值 364,000 美元，此前在上個季度又購買了 22,100 股。機構投資者和對沖基金持有公司 52.08% 的股份。</p>
</div><h2>Aadi Bioscience Company Profile</h2>
<div class="lb-trans"><h2>Aadi Bioscience 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.</p>
<div class="lb-trans"><p>Aadi Bioscience, Inc.是一家生物製藥公司，專注於開發和商業化針對具有 mTOR 通路基因改變的基因定義癌症的精準療法。其主要藥物候選產品為 FYARRO，一種用於治療晚期不可切除或轉移性惡性 PEComa 的注射用西羅莫司蛋白結合顆粒。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Aadi Bioscience</li>
<li>3 Small Caps With Big Return Potential</li>
<li>Bearish Investors Can Seek Refuge in Recession-Resistant ETFs</li>
<li>What is a Stock Market Index and How Do You Use Them?</li>
<li>3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?</li>
<li>3 Natural Gas Stocks That Offer Great Dividend Yields</li>
<li>3M to Hit $175 by Mid-Year, and Higher Highs Are Likely</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Aadi Bioscience</li>
<li>3 只小型股具有巨大的回報潛力</li>
<li>看跌投資者可以在抗衰退 ETF 中尋求避難所</li>
<li>什麼是股票市場指數，如何使用它們？</li>
<li>3 只超賣的七隻奇蹟股票處於關鍵水平：現在買入嗎？</li>
<li>3 只天然氣股票提供優厚的股息收益</li>
<li>3M 預計在年中達到 175 美元，且更高的高點可能性較大</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUFESQ" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=AADI"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Aadi Bioscience Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Aadi Bioscience 嗎？</h2>
</div><p>Before you consider Aadi Bioscience, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Aadi Bioscience 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aadi Bioscience wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 Aadi Bioscience 並不在名單上。</p>
</div><p>While Aadi Bioscience currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Aadi Bioscience 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

內幕交易：Aadi Biosciences, Inc.（納斯達克股票代碼：AADI）首席執行官出售 5690 股股票